A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
Titel:
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
Auteur:
Verstovsek, Srdan Courby, Stephane Griesshammer, Martin Mesa, Ruben A. Brachmann, Carrie Baker Kawashima, Jun Maltzman, Julia D. Shao, Lixin Xin, Yan Huang, Daniel Bajel, Ashish